ライフサイエンスコーパス: proguanil

1 eventing malaria than daily prophylaxis with proguanil.

2 ren who received IPT than those who received proguanil.

3 f patients took <75% of their daily doses of proguanil.

4 in drugs quinine, mefloquine, and atovaquone-proguanil.

5 nct from the activity of its parent compound proguanil.

6 uine was used in combination with atovaquone-proguanil.

7 ) per patient-year (PPY) at risk relative to Proguanil.

8 , six participants received daily atovaquone-proguanil 1 day before CHMI (cohort 1B), and six partici

9 amodiaquine (2.9%) and artesunate-atovaquone-proguanil (1.0%) groups.

10 lligrams of atovaquone and 400 milligrams of proguanil (1000/400 milligrams) on day -7.

11 ." The standard treatment dose of atovaquone/proguanil (250 mg/100 mg, 4 tablets/day for 3 days) prov

12 n additional group received daily atovaquone-proguanil (250-100 mg) for 9 days, starting 1 day before

13 lligrams of atovaquone and 100 milligrams of proguanil (250/100 milligrams) 1 day prior to infectious

14 lligrams of atovaquone and 200 milligrams of proguanil (500/200 milligrams) on day -7 or, (5) 1000 mi

15 s, as indicated by their hypersensitivity to proguanil, a drug that collapsed the membrane potential

16 To investigate suggestions that WR99210 and proguanil act against a target other than the reductase

17 re prodrugs analogous to the relationship of proguanil and its active metabolite cycloguanil.

18 Two drugs (proguanil and sulfasalazine) implicated in viral replica

19 amine, 1200 nM for cycloguanil, 13000 nM for proguanil, and 0.6 nM for P218.

20 n only (95 AL, 162 mefloquine, 36 atovaquone-proguanil [AP], and 17 others), and 87 were administered

21 w alternative non-ACTs, including atovaquone-proguanil, are currently available.

22 a-blocker propranolol, the antimalarial drug proguanil, certain antidepressants and barbiturates, and

23 before CHMI and six of six in the atovaquone-proguanil cohort were protected, whereas placebo recipie

24 nt to the synergistic effects of atovaquone/ proguanil combination.

25 prescribed the 3-day schedule of atovaquone/proguanil, completed at least 1 day before departure.

26 were also found for atovaquone, chloroquine, proguanil, cycloguanil and methylene blue.

27 anti-malarial drug used in combination with proguanil (e.g. Malarone(TM)) for the curative and proph

28 iaquine (SPAQ) was more effective than daily proguanil for malaria prevention in subjects with SCD.

29 was 0.04 episodes/PPY; relative to the daily Proguanil group, incidence rates were not significantly

30 ng secondary outcomes, relative to the daily Proguanil group, the incidence of painful events was not

31 ne and cycloguanil (the active metabolite of proguanil) have important roles in malaria chemopreventi

32 r Papua New Guinea, in which case atovaquone-proguanil is best, with mefloquine or quinine plus tetra

33 mutation in Pfdhfr that gives resistance to proguanil is reported in Ecuador for the first time.

34 The target of proguanil itself is separate from DHFR.

35 luate the effects of chloroquine, atovaquone/proguanil (Malarone), and doxycycline on the antibody re

36 d between groups, although compared to daily Proguanil (n = 2), more children died receiving monthly

37 tal of 246 children were randomized to daily Proguanil (n = 81), monthly SP-AQ (n = 83), or monthly D

38 oquine, chloroquine-proguanil) or atovaquone-proguanil on the incubation period.

39 e randomized to receive daily treatment with proguanil or IPT with either MQAS or SPAQ once every 2 m

40 tion therapies are not available, atovaquone-proguanil or quinine plus clindamycin is used for chloro

41 resistance, a combination of atovaquone and proguanil or quinine plus tetracycline or doxycycline or

42 ycline, mefloquine, chloroquine, chloroquine-proguanil) or atovaquone-proguanil on the incubation per

43 signed to artesunate-amodiaquine, atovaquone-proguanil, or artesunate-atovaquone-proguanil treatment

44 Allocation to DSM265, atovaquone-proguanil, or placebo was randomised by an interactive w

45 Single-dose atovaquone-proguanil provides effective malaria chemoprophylaxis ag

46 y, and acceptability of the 3-day atovaquone/proguanil schedule for malarial chemoprophylaxis.

47 The 3-day atovaquone/proguanil schedule had an impressively high compliance r

48 Children were assigned 1:1:1 to daily Proguanil (the standard of care), monthly sulfadoxine/py

49 terest in the antimalarial drugs WR99210 and proguanil, the cycloguanil precursor.

50 after artesunate-amodiaquine and atovaquone-proguanil therapies, respectively.

51 f susceptibility of transformed parasites to proguanil, thus providing evidence of intrinsic activity

52 rial to establish the efficacy of atovaquone-proguanil to prevent malaria with the goal of simulating

53 However, the proportion of atovaquone-proguanil-treated patients with positive smears on day 3

54 ovaquone-proguanil, or artesunate-atovaquone-proguanil treatment groups and followed for 28 days, acc

55 All participants received atovaquone/proguanil treatment if blood-stage infection was detecte

56 Artesunate-atovaquone-proguanil was a highly effective alternative treatment.

57 Atovaquone-proguanil was characterized by a slow blood schizontocid

58 Artesunate-atovaquone-proguanil was not associated with any failure.

59 onset after 60 days, while using atovaquone-proguanil was not.

60 odium falciparum infection relative to daily Proguanil was similar in the monthly SP-AQ group (IRR 0.

61 Atovaquone/proguanil was the most commonly prescribed antimalarial

62 fficacy against malaria, compared with daily proguanil, was 61% (95% confidence interval, 3%-84%) for

63 yrimethamine, cycloguanil, and P218, but not proguanil, which does not act directly against PfDHFR.